e-learning
resources
Berlin 2001
Sunday 23.09.2001
New developments in inhaler delivery systems
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Effect of the actuator orifice diameter on the biodisposition of a new budesonide CFC-free metered dose inhaler formulation
G. Poli, D. Acerbi, A. Simonon, A. Knops (Parma, Italy; Wavre, Antwerpen, Belgium)
Source:
Annual Congress 2001 - New developments in inhaler delivery systems
Session:
New developments in inhaler delivery systems
Session type:
Thematic Poster Session
Number:
718
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
G. Poli, D. Acerbi, A. Simonon, A. Knops (Parma, Italy; Wavre, Antwerpen, Belgium). Effect of the actuator orifice diameter on the biodisposition of a new budesonide CFC-free metered dose inhaler formulation. Eur Respir J 2001; 16: Suppl. 31, 718
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Mobile video directly observed therapy can be used to improve at-home inhaler technique in children with asthma
New inhaler devices: the good, the bad, and the ugly
Clinically appropriate testing of different valved holding chamber (VHC)-facemask combinations investigating simulated delivered mass to carina
Related content which might interest you:
Impact of inhalation delay on medication delivery from a salbutamol HFA pressurized metered dose inhaler used with and without a new prototype portable valved holding chamber
Source: International Congress 2019 – COPD treatment: clinical trials, cohorts and inhaler device studies
Year: 2019
Improvement in the drug delivery of salmeterol/fluticasone via a novel breath actuatedpressurized metered dose inhaler with a dose counter
Source: International Congress 2019 – COPD treatment: clinical trials, cohorts and inhaler device studies
Year: 2019
Pharmaceutical development of salmeterol HFA metered dose inhaler
Source: Eur Respir J 2004; 24: Suppl. 48, 582s
Year: 2004
Comparison of systemic pharmacodynamic effects of two HFA formulations of formoterol fumarate delivered by pressurised metered dose inhaler in healthy subjects
Source: Annual Congress 2009 - New aspects of inhalation therapy
Year: 2009
Assessment of the suitability of filters for use in clinical studies with an HFA fluticasone propionate pressurized metered dose inhaler (pMDI) and a valved holding chamber (VHC)
Source: Annual Congress 2011 - Lung function today and tomorrow II
Year: 2011
In vitro comparison of aerosol characteristics of HFA albuterol (salbutamol) pressurized metered dose inhaler (pMDI) formulation from three valved holding chambers (VHCs)
Source: Annual Congress 2011 - Drug delivery and pharmacokinetics II
Year: 2011
In vitro comparison of aerosol characteristics of HFA ipratropium bromide pressurized metered dose inhaler (pMDI) formulation from three valved holding chambers (VHCs)
Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I
Year: 2011
Efficacy and safety of two doses of budesonide/formoterol fumarate metered dose inhaler in COPD
Source: ERJ Open Res, 6 (2) 00187-2019; 10.1183/23120541.00187-2019
Year: 2020
Systemic effects and pharmacokinetics of a new CFC-free metered dose inhaler of beclomethasone dipropionate following multiple dosing in asthmatic patients
Source: Eur Respir J 2005; 26: Suppl. 49, 180s
Year: 2005
Assessment of relative potency of salbutamol administered
via
a metered-dose inhaler plus spacer or via a dry-powder inhaler in asthma patients
Source: Eur Respir J 2006; 28: Suppl. 50, 209s
Year: 2006
Comparison of proficiency of pressurized metered dose inhaler (pMDI) use with asthma control
Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of asthma
Year: 2008
In vitro evaluation of spacers in comparison with T-adapters in mechanical ventilation with pressurized metered dose inhalers (pMDI) and vibrating mesh nebulizer.
Source: International Congress 2019 – COPD and other specific entities in intensive care unit medicine
Year: 2019
A novel breath-actuated vortex spacer device increases respirable dose delivery of fluticasone/salmeterol in combination
Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of pulmonary diseases II
Year: 2008
Systemic activity of beclometasone dipropionate HFA and CFC formulations in metered dose inhalers assessed by knemometry
Source: Annual Congress 2010 - Managing asthma and allergic disease in children
Year: 2010
Technique: the usual problem of metered dose inhalers
Source: Eur Respir J 2002; 20: Suppl. 38, 503s
Year: 2002
Clinical equivalence of salmeterol/fluticasone propionate combination 50/100mcg
b.i.d.
delivered via DiskusÔ or CFC-free metered dose Inhaler (MDI) in children with asthma
Source: Eur Respir J 2003; 22: Suppl. 45, 311s
Year: 2003
Technique training doesn‘t improve patients ability to use pressurised metered dose inhalers (pMDIs)
Source: Annual Congress 2009 - Quality of treatment in primary respiratory care
Year: 2009
Bronchodilator response to salbutamol administered through metered-dose inhaler plus spacer or dry-powder inhaler in asthmatic patients
Source: Eur Respir J 2001; 18: Suppl. 33, 101s
Year: 2001
Objective measurement of inhalation profiles in patients using metered dose inhalers (MDIs)
Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I
Year: 2011
Efficacy and safety of budesonide/formoterol fumarate dihydrate metered dose inhaler (BFF MDI) using co-suspension delivery technology compared to monocomponents and an active comparator in COPD
Source: International Congress 2018 – Pharmacological management of COPD
Year: 2018
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept